

Meeting Minutes



Institution:	Inovio Pharmaceuticals Inc.		
Meeting Date:	April 23, 2026		
Meeting Time	1:00 PM Pacific Time		
Meeting Type:	Virtual Platform Teleconference (Remote) Open to the Public		
Members in Attendance:	Member	Voting	Member Type
	Noriea, Nicholas	Yes	Chair: Biosafety Expert/HGT Expert
	Wang, Anthony	Yes	Core Member: Biosafety Expert/HGT Expert
	Rastein, Daniel	Yes	Core Member: Biosafety Expert/HGT Expert
	Ramil, Jennifer	Yes	Local Unaffiliated Member
	Hall, David	Yes	Local Unaffiliated Member
	Humeau, Laurent	Yes	Core Member: Laboratory Science Expert
	Smith, Trevor	Yes	Core Member: Laboratory Science Expert
	Vega Vega, Francisco	Yes	Site Contact
Invited Members Not in Attendance:	Member	Voting	Member Type
Guests:	Guimet, Diana; Agnes, Joseph		
Staff:	Christine McFarland and Tammy Bavaret		

Call to Order: The IBC Chair called the meeting to order at 1:02 PM Pacific Time. A quorum was present as defined in the Sabai IBC Charter.

Meeting Minutes

Conflicts of Interest: The IBC Chair reminded all members present to identify any conflicts of interest (COI). The Chair noted that all institutional committee members associated with the research are recused from voting on the study under review today. The Committee members agreed and had no concerns. One IBC member noted a business relationship unrelated to the research. They stated that their role is primarily as a participant in research oversight committee reviews and not in the actual testing of Inovio products and confirmed they can be objective during review of today's study.

Public Comments: No public comments were made prior to or at the meeting.

Review of Prior Business: None

Previous Meeting Minutes: Minutes from 4/28/25 were approved with no comments.

New Business:

PI:	Smith, Trevor
Sponsor:	Inovio Pharmaceuticals, Inc.
Protocol:	INO-001: R&D Umbrella Protocol
Review Type:	Annual Review and Change in Research
NIH Guidelines Section:	III-E and III-F

Trial Summary: Inovio Pharmaceutical is a biotechnology company focused on developing DNA-based vaccines and immunotherapies. The company has established a strong product pipeline leveraging its bacterial and mammalian plasmid DNA platforms for the clinical development of proprietary vaccine and immunotherapy candidates treat cancer and infectious diseases. Product characterization assays, including *in vitro* biological assays, are performed on site following established protocols and SOPs.

Biosafety Containment Level (BSL): BSL-1: Research with bacterial plasmids, non-pathogenic *E.coli*, fixed mammalian cells, and mammalian cell lysates. BSL-2: Research with viable mammalian cells, with or without recombinant agents.

Risk Assessment and Discussion:

- The Committee reviewed the Site procedures, facilities and supplemental documentation related to the recombinant or synthetic nucleic acid molecules and the proposed research activities.
 - In summary, the primary risks in this research include potential occupational exposure from accidental spills or splashes of the research materials being handled, as well as the potential for sharps injuries, to the extent any sharps are used during preparation/handling of research materials. These potential risks are mitigated through a

Meeting Minutes



- combination of relevant staff training, safe practices and the use of appropriate PPE (as described and documented in the IBC submission package).
 - The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the study materials will handle research materials and equipment.
 - The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the research materials.
 - The Site confirmed that staff members receive Bloodborne Pathogens and IATA shipping training.
 - Occupational Health Recommendations: None
 - The Committee discussed the nucleic acid sequences of research interest. The Site confirmed these sequences are typically classic antigen targets including membrane proteins. Functional proteins assessed are related to antibody analysis. The Site also confirmed any oncogenes expressed are modified to render them non-oncogenic. The Site was asked to update their Research Summary to include these additional details. The Committee had no further concerns or comments.
 - The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the research materials under study or the proposed mitigation strategies.
- The Committee reviewed the Site's facility details, relevant study-specific procedures and practices, the annual review report form, and other applicable information provided by the Site for the purposes of the IBC review. The PI's CV and signed Certificate of Training and Responsibilities (CTR form) were available for Committee review.
 - The Site confirmed that the Annual Review Report was accurate as presented.
 - The Site confirmed that the Chair's review of the Site's arrangements and activities was accurate as described.
 - In response to a question from the Committee, the Site stated that the capacity of the bioreactor is 4x1 liters. The Committee had no further concerns and asked that the photo slide deck be administratively updated to include this information.
 - In response to a question from the Committee, the Site confirmed that no infectious materials are placed inside the clean bench pictured in one of the photos. The Committee had no additional concerns and asked that the photo slide deck be administratively annotated to reflect this information.

Motion: A motion of Full Approval for the study at BSL-1 for general cloning and non-pathogenic bacterial work and BSL-2 for all live mammalian cell and tissue work was passed by unanimous vote. There were 0 votes against and 2 abstentions.

- Contingencies stated by the Committee: None
- Stipulations stated by the Committee: None

Meeting Minutes

Review of Incidents: Nothing to report.

IBC Training: Nothing to report.

Reminder of IBC Approval Requirements.

Adjournment: The IBC Chair adjourned the meeting at 1:37 PM Pacific Time.

Post-Meeting Pre-Approval Note: None